Black Diamond Therapeutics Announces Initial Phase 2 Data …
WEB1 day ago · BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed Preliminary ORR of 42% in 19 patients at 200 mg with on-target ...
Black Diamond Therapeutics Announces Initial Phase 2
WEB1 day ago · BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed. Preliminary ORR of 42% in 19 patients at 200 mg with on-target ...
Black Diamond Therapeutics Gains On Positive Phase 2 Data For BDTX-1535 …
WEB1 day ago · (RTTNews) - Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or refractory non-small cell lung cancer also known as NSCLC ...
Black Diamond Therapeutics Announces Initial Phase 2 Data
WEB1 day ago · BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed. Preliminary ORR of 42% in 19 patients at 200 mg with on-target ...
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial …
WEB1 day ago · Monday, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported initial Phase 2 data of BDTX-1535. The data demonstrated encouraging clinical responses and durability of BDTX-1535 in patients with ...
BDTX-1535 Initial Phase 2 Data in Patients With Recurrent EGFRm …
WEBBDTX-1535 GBM BDTX-4933 BDTX-4876 Presentations and Publications Patients Clinical Trials Expanded Access Investors & News Overview Press Releases Events & Presentations Corporate Governance Stock Information SEC Filings Analyst Coverage Investor Resources Join Us ...
Black Diamond Therapeutics Presents Promising BDTX-1535
WEBJun 1, 2024 · Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment
Black Diamond Therapeutics to Host Webcast Presentation of …
WEB2 days ago · Webcast to be held Monday, September 23, at 8:00 a.m. ET. CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with ...
Black Diamond Therapeutics Announces Topline Results from
WEBDec 13, 2023 · BDTX-1535, a fourth-generation, brain-penetrant, covalent EGFR inhibitor, is under investigation in a Phase 1 clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC)...
Black Diamond Therapeutics Announces Initial Phase 2 Data
WEB1 day ago · BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed. Preliminary ORR of 42% in 19 patients at 200 mg with on-target resistance EGFR mutations. ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to ...
- Some results have been removed